China Pharma Holdings, Inc. (CPHI) Stock Price & Analysis

China Pharma Holdings, Inc. Company Overview

China Pharma Holdings, Inc. (CPHI) operates within the challenging Drug Manufacturers - Specialty & Generic industry in China, focusing on generic and branded pharmaceuticals. With a small market capitalization of $4 million and an FMP rating of C (2/5), CPHI faces significant headwinds, reflected in its negative gross margin of -7.9%. Key growth drivers include expanding its product portfolio and penetrating deeper into existing markets. The investment thesis hinges on CPHI's ability to improve operational efficiency and capitalize on the growing demand for generic drugs in China. However, investors must weigh the potential for turnaround against the company's current financial struggles and competitive landscape, presenting a high-risk, high-reward scenario.

China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical and biochemical products in China. The company offers a range of generic and branded products, including injectables, tablets, and capsules, targeting hospitals and private retailers.

Key Facts

• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic
• Headquarters: Haikou, CN
• CEO: Zhilin Li
• Employees: 224

What China Pharma Holdings, Inc. Does

Develops generic pharmaceutical products.,Manufactures pharmaceutical products in various forms, including injectables, tablets, and capsules.,Markets pharmaceutical products to hospitals and private retailers in China.,Offers products for treating conditions such as memory decline, fatigue, and cardiovascular diseases.,Provides medications for infections, hypertension, and edema.,Distributes products through a network of distributors and sales representatives.,Offers food supplements and sanitizers.

Business Model

Develops and manufactures generic and branded pharmaceutical products.,Sells products to hospitals and private retailers in China.,Utilizes a distribution network and a direct sales force to reach customers.,Focuses on both prescription and over-the-counter medications.

Key Competitors

Unknown

CPHI Investment Analysis

Investment Thesis

The investment thesis for China Pharma Holdings, Inc. centers on its potential to capitalize on the growing demand for generic pharmaceuticals in China. With a small market capitalization, CPHI's ability to improve its operational efficiency and expand its product portfolio is crucial. Key value drivers include increasing market penetration and reducing its negative gross margin. Growth catalysts involve expanding into new therapeutic areas and leveraging its existing distribution network. However, investors must consider the company's current financial struggles, including a negative profit margin of -76.9% and a highly competitive landscape. The company's success hinges on its ability to execute its turnaround strategy and achieve profitability.

Growth Catalysts

• Ongoing: Expansion of product portfolio with new generic drug approvals.
• Ongoing: Increased market penetration in existing geographic regions.
• Ongoing: Government policies supporting generic drug usage in China.
• Upcoming: Potential strategic partnerships or acquisitions to expand capabilities.

Risk Factors

• Ongoing: Intense competition from other generic drug manufacturers in China.
• Ongoing: Pricing pressures and regulatory changes affecting the pharmaceutical industry.
• Potential: Quality control and compliance issues related to manufacturing processes.
• Potential: Economic slowdown in China impacting healthcare spending.

Analyst Coverage for CPHI

CPHI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our multi-factor AI model evaluates CPHI against Healthcare peers and assigns an underweight signal based on the underlying data. Peer-relative metrics and sector momentum carry more weight for CPHI until institutional coverage emerges.

Questions & Answers

Is CPHI a good stock to buy?

Whether CPHI is a suitable investment depends on your goals, risk tolerance, and time horizon. Evaluate China Pharma Holdings, Inc.'s revenue growth, profit margins, debt levels, and valuation relative to peers. This is not financial advice—consult a qualified advisor before investing.

What is the CPHI MoonshotScore?

The MoonshotScore rates CPHI from 0 to 100 across growth potential, financial health, market momentum, and risk factors. It is updated as market data refreshes. This score is informational only—not a buy or sell recommendation.

How often is CPHI data updated?

CPHI's price is the last quote we recorded, from the Oct 5, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update as market data refreshes.

What are the risks of investing in CPHI?

Risk categories for CPHI include market risk, company-specific risk, financial risk (debt, cash burn), and macroeconomic risk. Review the Risk Factors section for details specific to this stock. All investments carry risk of loss.